Lapatinib Impurity4;1152131-73-1
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: L079004
English Name: Lapatinib Impurity 4
English Alias: 5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-carboxylic acid
CAS Number: 1152131-73-1
Molecular Formula: C26H17ClFN3O4
Molecular Weight: 489.88
Product Advantages: Lapatinib Impurity 4 has extremely high purity and excellent chemical stability. Its structure has been accurately confirmed by various precise analytical methods (such as nuclear magnetic resonance and mass spectrometry). Under different experimental environments and storage conditions, this impurity shows stable and uniform properties. It can be used as a reliable reference substance for Lapatinib impurity analysis, ensuring that the detection results are highly accurate and reproducible, and providing a solid foundation for pharmaceutical quality research and quality control.
Application Fields:
Pharmaceutical Quality Control: As an impurity reference standard, it is used to establish and validate the detection methods for impurities in Lapatinib bulk drugs and formulations, ensuring that the sensitivity and specificity of the detection methods meet pharmaceutical quality standards.
Production Process Optimization: During the production of Lapatinib, by monitoring the content of this impurity and tracing its source, it helps to optimize the synthesis process, reduce impurity generation, and improve drug quality.
Drug Stability Studies: In drug stability tests, it analyzes the change trends of this impurity under different storage conditions (such as temperature, humidity, light), providing key data support for determining the shelf life and suitable storage conditions of drugs.
Background Description: Lapatinib is a key targeted drug for the treatment of HER2-positive breast cancer. In the process of its research, development, production, and quality control, impurity research plays a decisive role in ensuring drug safety and effectiveness. The presence of impurities may not only reduce drug efficacy but also pose potential safety risks. As a related impurity of Lapatinib, in-depth research on Lapatinib Impurity 4 helps to comprehensively and accurately evaluate the quality of Lapatinib drugs, providing strong support for safe clinical medication.
Research Status: Currently, research on Lapatinib Impurity 4 continues to deepen. In terms of detection technology, researchers are constantly exploring advanced detection methods such as Ultra-Performance Liquid Chromatography - Tandem Mass Spectrometry (UPLC - MS/MS) and high-resolution mass spectrometry, aiming to achieve high-precision detection of trace impurities. In the study of impurity generation mechanisms, the formation causes and influencing factors of this impurity are deeply analyzed by simulating drug synthesis routes and storage environments, providing a theoretical basis for controlling impurities from the source. In addition, research on the impact of this impurity on the efficacy and safety of Lapatinib is also gradually being carried out, with the aim of further improving the comprehensive understanding of the quality of Lapatinib drugs
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China